Accure Acne Inc.

Accure Acne Inc. is a privately-owned medical device company focused on developing an innovative and highly efficient solution to reducing and/or preventing the recurrence of acne vulgaris.

Accure Acne Inc.

Accure Acne Inc. is a privately-owned medical device company focused on developing an innovative and highly efficient solution to reducing and/or preventing the recurrence of acne vulgaris. The company’s patented and patent-pending laser technology was designed to help improve acne sufferers’ long-term quality of life by offering a differentiated and impactful solution.

Leveraging the extensive experience of its management and scientific teams, paired with a clear go-to-market strategy and commercialization and regulatory expertise, Accure remains committed to developing a uniquely compelling value proposition.

Accure Acne is headquartered in Boulder, Colorado. The company’s flagship product, the Accure Laser System, was granted CE Mark approval for the treatment of moderate inflammatory acne in 2020, which allows the company to commercialize its product in the European Union while working to develop an exclusive global IP portfolio.

Accure Laser System

The company’s pioneering technology has the potential to disrupt the vast global market of acne therapeutics. It is estimated that there are 40-50 million people affected by acne vulgaris in the United States each year, while roughly 85 percent of the global population will suffer from acne at some point, according to the company’s April 2021 investor presentation. In 2016, the acne vulgaris market was estimated at $2.6 billion in the U.S. alone.

Accure Acne is leveraging several competitive advantages to position itself as a leading company in the acne treatment market. Compared to the main competitors and other acne treatments in the market, the Accure Laser System is designed for efficacy and durable results, in a cost-effective treatment package.

This groundbreaking system is the first commercially developed energy-based device that selectively targets and neutralizes overactive sebaceous glands present in the skin, which are the main source of sebum production and acne vulgaris. By targeting only overactive glands without damaging the surrounding epidermis, the Acne Laser System is likely to yield a durable response, starting with a significant reduction of inflammatory acne lesions, with the goal of eliminating inflammation recurrence in treated areas. The system has been shown to yield a 45%+ reduction in inflammation after just one treatment.

Other key features of the Accure Laser System include:

  • Utilizes a unique wavelength that has not previously been clinically available
  • Leverages unique pulsing strategy, precise and safe closed-loop laser control and integrated temperature monitoring through an infrared camera
  • Is designed for ease of use and relatively short treatment time (30 to 45 minutes)
  • Is equipped with single-use treatment tip and accessories

Treatments are customized to each patient, depending on skin types and case severity, and can range from one to six treatment sessions administered three to six weeks apart.

Accure Acne believes its technology is the only 1,726 nm laser with CE Mark Clearance for acne treatment on the market. The Accure Laser System was developed in partnership with Quanta System, a Milan, Italy, laser tech developer with over four decades of experience.

The company has already launched an early adopter program in the European Union, with the first orders received and delivered in Italy in Q2 2021, through Quanta’s distribution channel. A broader EU commercial launch is scheduled for H2 2021, with plans for an early adopter program in the U.S. to begin in H1 2022 and broader commercial launch in H2 2022.

New Pivotal Acne Study

The Accure Laser System’s efficiency and safety of treatment across all genders, ages, races and skin types has so far been confirmed through four IRB-approved clinical studies. Research showed a 45% reduction of acne lesions after just one treatment and an 80% reduction after the fourth treatment.

Accure Acne is now conducting a new pivotal acne study, restarted in January 2021, based on safety reports from the four IRB-approved clinical trials. This open-label study will enroll 75 patients 16 years and older who will undergo four treatments approximately one month apart.

The study is expected to be completed in early 2022, following several checkpoints to monitor for progress and durability – at three months, six months, nine months and 12 months after the fourth and final treatment. This clinical trial will be key to the company’s efforts to secure FDA approval in the United States.

Private Placement Offering

Accure Acne launched a private placement offering pursuant to Rule 506(c) of Regulation D under the Securities Act. The private placement, launched in April 2021 on the M-Vest platform, aims to raise up to $20 million in Series A Convertible preferred stock.

The proceeds will be used to fund the pivotal acne study, ongoing operations and infrastructure needs, while also creating an EU-based sales team and global marketing teams and conducting pre-commercialization operations in the U.S.

For more information, visit the company’s offering page on M-Vest.

Management Team

Christopher Carlton is Co-Founder, Chief Executive Officer and Chairman of the Board of Accure Acne. He has extensive industry experience as well as a demonstrated track record of entrepreneurial success with high-growth public companies and new product launches on the global medical and aesthetic markets. His previous tenures include CEO of Quanta Aesthetic Lasers USA LLC; President, NA for Syneron-Candela, a prominent company in the aesthetic energy-based device market; Vice President and Global General Manager – Interventional Oncology for Covidien Ltd.; CEO for SRI Surgical; and other leadership positions. In 2016, he was recognized as one of the top 10 CEOs and presidents in the industry by Aesthetics Everything(R). Mr. Carlton is a graduate of the GE Management Development Institute-Crotonville and the Program on Negotiation at Harvard Law School, and he holds a BS in Industrial Engineering (With Honors), a Graduate Diploma in Management and an MBA.

R. Rox Anderson, MD, is the company’s Co-Founder and Chief Scientific & Medical Officer. One of the most influential scientists in the field of energy-based devices in aesthetics and widely considered the father of the aesthetic industry, Dr. Anderson has contributed significant advancements to acne treatment efforts, including pre-clinical, clinical and product development activities built upon his conceptualization and co-development of microscopic target-selective laser therapy. He has been awarded over 60 national and international patents and has co-authored over 437 scientific books and papers cited by other researchers more than 22,800 times. Dr. Anderson is a Harvard Medical School Professor in dermatology, Director of the Wellman Center for Photomedicine, and adjunct Professor of Health Sciences and Technology at Massachusetts Institute of Technology.

Edward Barbera is Co-Founder and Director of Accure Acne. He has more than 35 years of experience developing, running and investing in startups, as well as fundraising, having secured more than $50 million in private equity for a company he founded. Mr. Barbera began his career as a Senior Consultant with Peat, Marwick, Mitchell & Co. and has since held key leadership roles in business development, acquisitions, capital formation and the operation of numerous startups. He has a Bachelor of Business Administration degree with a major in accounting from the University of Massachusetts – Amherst and has previously been a member of the National and Colorado Societies of CPAs.

The Accure Acne leadership and medical teams are further comprised of experts and professionals with extensive experience in technology, software, engineering and medical devices, as well as specialists in acne treatment and laser-based treatment options in dermatology and other medical fields.

Investment Considerations
  • Accure Acne’s groundbreaking Accure Laser System is the first commercially developed energy-based device that selectively targets and neutralizes overactive sebaceous glands.
  • The innovative technology is expected to position Accure as a disruptor on the vast global market of acne treatments.
  • By targeting only overactive glands, the system offers enhanced efficacy and a durable response; safety and efficacy have been confirmed by four IBR-approved clinical trials.
  • An early adopter program is already underway in the European Union, with the first orders received and delivered in Italy in Q2 2021; a broader commercial launch in several European countries is currently slated for H2 2021.
  • The company restarted a pivotal acne study in January 2021, with initial results expected in early 2022; this study will be essential for FDA approval in view of beginning U.S. commercialization in 2022.
  • Accure Acne boasts highly experienced management and scientific teams, leveraging decades of expertise in the aesthetics and medical device markets.
  • The company was co-founded by one of the most influential scientists in the field of energy-based devices and the co-developer of microscopic target-selective laser therapy.
Additional Resources


Request Additional Information & Receive Ongoing Updates

Interested in additional information regarding Accure Acne Inc. and other companies IBN covers?

Request Information

Accure Acne Inc.Company News & Information
News & Media Overview Chart Financials Filings Time & Sales Historical Data

Let's get started.

Interested in a live, online demonstration? Schedule a date and time that works for you.

Schedule a LIVE Demo

Questions about IBN and our solutions? Call or send us an email.

(310) 299-1717

View All Solutions

You’re already more familiar with brand awareness than you might think. What’s your favorite brand of soft drink, athletic shoe, car, shampoo, streaming content provider? Chances are, you first tried those brands because of their awareness strategies. Whether it was word of mouth or a TV commercial, Facebook post, billboard or coupon, that awareness peaked interest, triggered a purchase reaction, and ideally built customer loyalty.

More About Brand Awareness

5,000+ key syndication outlets across the country. IBN’s extensive system of strategic distribution points maximizes your exposure to an audience of millions, including journalists, investors, day traders, fund managers and a multitude of other interested individuals. Now your press releases, earnings statements, branded articles, shareholder updates, corporate achievements can reach a vast and diverse nationwide audience.

More About InvestorWire

Make sure your message resonates. IBN integrates social media with traditional distribution channels to make sure your message resonates long after initial publication. This innovative model ensures that your news not only crosses the wire, but keeps reverberating via social conversation on Twitter, Facebook, LinkedIn and other social networks.

More About Social MediaIBN Social Media NetworkSocial Media Statistics & FAQs

A unique format with a traditionally different sensory input – hearing.As conferences and events continue to suffer cancellations and greatly reduced attendance, many businesses are wondering how to network with large investor audiences in the new normal. At the same time podcasts have seen a jump in popularity.

More About IBN Podcast Solutions